Open AccessEndocrine Treatment with 2 Years of Tamoxifen versus 2 Years of Exemestane in Postmenopausal Patients with High-Risk Early Breast Cancer and Persisting Circulating Tumor Cells - First Results of the SUCCESS C Endocrine Treatment Sub-Study
Author(s) -
Fabienne Schochter,
Brigitte Rack,
M Tzschaschel,
A Polasik,
Ulrich Andergassen,
E Trapp,
Marianna Alunni-Fabbroni,
Andreas Schneeweiß,
Volkmar Müller,
Klaus Pantel,
J Gade,
Ralf Lorenz,
Mahdi Rezai,
Hans Tesch,
Ulrike Soeling,
Tanja Fehm,
Sven Mahner,
Christian Scheffold,
W. Lichtenegger,
Matthias W. Beckmann,
Peter A. Fasching,
W Janni,
Thomas W. P. Friedl
Publication year - 2018
Publication title -
oncology research and treatment
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.553
H-Index - 48
eISSN - 2296-5262
pISSN - 2296-5270
DOI - 10.1159/000485566
Subject(s) - exemestane , medicine , tamoxifen , tolerability , breast cancer , oncology , adverse effect , cancer , gynecology
Optimal choice and sequence of endocrine treatment following adjuvant chemotherapy in postmenopausal early breast cancer patients are still under discussion and treatment stratification factors are missing.